{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-006182","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.510065+00:00","generated_at":"2026-05-16T03:48:42.845946+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BD Q1 revenue $5.25B beats; closes Waters deal; affirms FY26 guidance","bullets":["Revenue $5.252B (+1.6% reported, +0.4% FX neutral); GAAP EPS $1.34, adjusted EPS $2.91.","BD to close combination of Biosciences & Diagnostic Solutions business with Waters Corporation on Feb 9, 2026.","Affirms FY26 revenue growth guidance; provides New BD adjusted diluted EPS guidance.","Announced $110M investment for Neopak syringe production in Nebraska; FDA clearance for EnCor EnCompass biopsy system.","Adjusted diluted EPS $2.91, down 15.2% YoY on reported basis but beat expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-006182","json":"https://secwatch.observer/filing/0001628280-26-006182.json","markdown":"https://secwatch.observer/filing/0001628280-26-006182.md","text":"https://secwatch.observer/filing/0001628280-26-006182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000162828026006182/0001628280-26-006182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000162828026006182/bdx-20260209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:48:42.845946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}